The 2024 TIL Industrialization Summit clarifies the TIL industry's past, present, and future trajectory. [Photo/jiading.gov.cn]
Juncell Therapeutics inaugurated its state-of-the-art TIL (Tumor Infiltrating Lymphocyte) cell industrialization base on Dec 18 in the Anting International Medical Industry Park in Jiading district, Shanghai, marking a significant leap forward in the development of precision anti-tumor therapies.
The base, a center of innovation, aims to revolutionize solid tumor treatments with its advanced TIL cell therapies. It spans 16,000 square meters and boasts an annual capacity of 6,000 to 10,000 cases, setting new standards in the field.
As a world-leading cell industrialization base with the world's largest designed capacity, the highest construction standards, and most intelligent facilities, it is expected to drive the high-quality development of TIL products and accelerate the transformation of disruptive innovative technologies into new quality productive forces in biomedicine.
At the 2024 TIL Industrialization Summit held alongside the opening, experts and industry leaders gathered to discuss the future of the TIL industry. Juncell Therapeutics' breakthroughs in TIL therapy, now in phase II clinical research, showcase China's prowess in global biopharmaceuticals.
This milestone underscores China's advancement in cell therapy. With a focus on unmet clinical needs, Juncell Therapeutics remains dedicated to enhancing cancer treatments and driving genetic cell industry progress.
The summit also saw the release of national TIL group standards and a white paper, providing crucial guidelines for industry players and shedding light on the industry's trajectory.